Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Study Classification
OBSERVATIONAL
Study Start Date
1988-12-31
Study Completion Date
1993-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
To acquire a better understanding of the spontaneous clinical behavior of paroxysmal tachycardia by studying epidemiologic features of symptomatic tachycardia patients.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Telemetric Arrhythmia and Syncope Diagnosis - Evaluation of Arrhythmia Treatment Efficacy
NCT01265303
Atrial Fibrillation
Arrhythmias, Cardiac
UNKNOWN
NA
AV Nodal Reentrant Tachycardia Study
NCT00618683
Tachycardia, Atrioventricular Nodal Reentry
COMPLETED
NA
Identifying High Risk Patients With Syncope
NCT00005202
Cardiovascular Diseases
Arrhythmia
Death, Sudden, Cardiac
+2 more
COMPLETED
Prevalence of Asymptomatic Ventricular Dysfunction
NCT00005534
Cardiovascular Diseases
Heart Diseases
Heart Failure, Congestive
+1 more
COMPLETED
Characterization of Arrhythmia-induced Cardiomyopathy
NCT05662293
Cardiomyopathy
Arrhythmia-induced Cardiomyopathy (AiCM)
RECRUITING
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
BACKGROUND:
Paroxysmal arrhythmias are a group of disorders in which sudden abnormalities of the cardiac rhythm occur without warning. Despite the abundant information available from studies on the mechanisms of tachycardias, there was hardly a shred of objective data in 1989 to establish how the occurrence of symptomatic tachycardias was influenced by various mechanisms. In fact, there were very few objective data describing the occurrence of symptomatic tachycardia among the patients who were afflicted with various paroxysmal tachycardias. For example, were patients in normal sinus rhythm likely to remain free of their tachycardia for one day, one week, one month, or longer? The suddenness and apparent unpredictability of attacks of paroxysmal tachycardias have been substantial obstacles to quantitative description of their occurrence. These studies used careful documentation of spontaneous tachycardia to establish the epidemiology of symptomatic arrhythmias.
DESIGN NARRATIVE:
Baseline electrophysiologic methods, including intracardiac recording and programmed electrical stimulation, were used to determine the mechanism of paroxysmal supraventricular tachycardia. All patients had antiarrhythmic medications stopped. In most cases, the diagnosis of atrial fibrillation was established by scalar electrocardiographic criteria. At the time of entry into follow-up each patient was given a cardiobeeper and instructed to record and transmit any symptomatic arrhythmia when it occured. Descriptive information about each patient was entered into a baseline data file which included information on the time interval between attacks, age, sex, mechanism of arrhythmia, types of associated heart diseases, ECG data during sinus rhythm, and date and time of call. The purpose of the outpatient follow-up was to obtain objective documentation of spontaneously occurring, symptomatic tachycardia for quantitative analyses. Holter monitoring was used in patients with paroxysmal tachycardias to establish that asymptomatic tachycardia did not occur so often that it constituted an important, unrecognized feature of these clinical conditions.
Ten consecutively referred patients with paroxysmal supraventricular tachycardia and ten consecutively referred patients with atrial fibrillation underwent untreated surveillance with telephone/ cardiobeeper monitoring for symptomatic arrhythmias and had four 24-hour ambulatory ECGs recorded at weekly intervals to detect symptomatic and asymptomatic arrhythmias. The Cox proportional hazards model was used to test the hypothesis that the mechanism of tachycardia was the most important predictor of the tachycardia-free period during an untreated observation period.
The study completion date listed in this record was obtained from the "End Date" entered in the Protocol Registration and Results System (PRS) record.
Paroxysmal arrhythmias are a group of disorders in which sudden abnormalities of the cardiac rhythm occur without warning. Despite the abundant information available from studies on the mechanisms of tachycardias, there was hardly a shred of objective data in 1989 to establish how the occurrence of symptomatic tachycardias was influenced by various mechanisms. In fact, there were very few objective data describing the occurrence of symptomatic tachycardia among the patients who were afflicted with various paroxysmal tachycardias. For example, were patients in normal sinus rhythm likely to remain free of their tachycardia for one day, one week, one month, or longer? The suddenness and apparent unpredictability of attacks of paroxysmal tachycardias have been substantial obstacles to quantitative description of their occurrence. These studies used careful documentation of spontaneous tachycardia to establish the epidemiology of symptomatic arrhythmias.
DESIGN NARRATIVE:
Baseline electrophysiologic methods, including intracardiac recording and programmed electrical stimulation, were used to determine the mechanism of paroxysmal supraventricular tachycardia. All patients had antiarrhythmic medications stopped. In most cases, the diagnosis of atrial fibrillation was established by scalar electrocardiographic criteria. At the time of entry into follow-up each patient was given a cardiobeeper and instructed to record and transmit any symptomatic arrhythmia when it occured. Descriptive information about each patient was entered into a baseline data file which included information on the time interval between attacks, age, sex, mechanism of arrhythmia, types of associated heart diseases, ECG data during sinus rhythm, and date and time of call. The purpose of the outpatient follow-up was to obtain objective documentation of spontaneously occurring, symptomatic tachycardia for quantitative analyses. Holter monitoring was used in patients with paroxysmal tachycardias to establish that asymptomatic tachycardia did not occur so often that it constituted an important, unrecognized feature of these clinical conditions.
Ten consecutively referred patients with paroxysmal supraventricular tachycardia and ten consecutively referred patients with atrial fibrillation underwent untreated surveillance with telephone/ cardiobeeper monitoring for symptomatic arrhythmias and had four 24-hour ambulatory ECGs recorded at weekly intervals to detect symptomatic and asymptomatic arrhythmias. The Cox proportional hazards model was used to test the hypothesis that the mechanism of tachycardia was the most important predictor of the tachycardia-free period during an untreated observation period.
The study completion date listed in this record was obtained from the "End Date" entered in the Protocol Registration and Results System (PRS) record.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Cardiovascular Diseases
Heart Diseases
Atrial Fibrillation
Arrhythmia
Tachycardia
Tachycardia, Supraventricular
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
No eligibility criteria
Maximum Eligible Age
100 Years
Eligible Sex
MALE
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Sponsor Role
lead
References
Explore related publications, articles, or registry entries linked to this study.
Riley RD, Pritchett EL. Pharmacologic management of atrial fibrillation. J Cardiovasc Electrophysiol. 1997 Jul;8(7):818-29. doi: 10.1111/j.1540-8167.1997.tb00841.x.
Reference Type
BACKGROUND
Hamer ME, Wilkinson WE, McCarthy EA, Page RL, Pritchett EL. Heart rate during spontaneous and induced paroxysmal supraventricular tachycardia. Pacing Clin Electrophysiol. 1995 Dec;18(12 Pt 1):2155-7. doi: 10.1111/j.1540-8159.1995.tb04641.x.
Reference Type
BACKGROUND
Pritchett ELC: Afternoon Arrhythmia. Med Aspects Human Sex, 23:16, January 1989
Reference Type
BACKGROUND
Greer GS, Wilkinson WE, McCarthy EA, Pritchett EL. Random and nonrandom behavior of symptomatic paroxysmal atrial fibrillation. Am J Cardiol. 1989 Aug 1;64(5):339-42. doi: 10.1016/0002-9149(89)90531-6.
Reference Type
BACKGROUND
Vitullo RN, Wharton JM, Allen NB, Pritchett EL. Trazodone-related exercise-induced nonsustained ventricular tachycardia. Chest. 1990 Jul;98(1):247-8. doi: 10.1378/chest.98.1.247.
Reference Type
BACKGROUND
Linzer M, Pritchett EL, Pontinen M, McCarthy E, Divine GW. Incremental diagnostic yield of loop electrocardiographic recorders in unexplained syncope. Am J Cardiol. 1990 Jul 15;66(2):214-9. doi: 10.1016/0002-9149(90)90591-n.
Reference Type
BACKGROUND
Linzer M, Pontinen M, Gold DT, Divine GW, Felder A, Brooks WB. Impairment of physical and psychosocial function in recurrent syncope. J Clin Epidemiol. 1991;44(10):1037-43. doi: 10.1016/0895-4356(91)90005-t.
Reference Type
BACKGROUND
Weiner HL, McCarthy EA, Pritchett EL. Regular ventricular rhythms in patients with symptomatic paroxysmal atrial fibrillation. J Am Coll Cardiol. 1991 May;17(6):1283-7. doi: 10.1016/s0735-1097(10)80136-6.
Reference Type
BACKGROUND
Clair WK, Wilkinson WE, McCarthy EA, Pritchett EL. Treatment of paroxysmal supraventricular tachycardia with oral diltiazem. Clin Pharmacol Ther. 1992 May;51(5):562-5. doi: 10.1038/clpt.1992.63.
Reference Type
BACKGROUND
Pritchett EL, Wilkinson WE. New drug application strategies for supraventricular arrhythmias. Clin Pharmacol Ther. 1991 May;49(5):481-7. doi: 10.1038/clpt.1991.58. No abstract available.
Reference Type
BACKGROUND
Pritchett EL, McCarthy EA, Wilkinson WE. Propafenone treatment of symptomatic paroxysmal supraventricular arrhythmias. A randomized, placebo-controlled, crossover trial in patients tolerating oral therapy. Ann Intern Med. 1991 Apr 1;114(7):539-44. doi: 10.7326/0003-4819-114-7-539.
Reference Type
BACKGROUND
Hamer ME, Clair WK, Wilkinson WE, Greenfield RA, Pritchett EL, Page RL. Evaluation of outpatients experiencing implantable cardioverter defibrillator shocks associated with minimal symptoms. Pacing Clin Electrophysiol. 1994 May;17(5 Pt 1):938-43. doi: 10.1111/j.1540-8159.1994.tb01436.x.
Reference Type
BACKGROUND
Hamer ME, Wilkinson WE, Clair WK, Page RL, McCarthy EA, Pritchett EL. Incidence of symptomatic atrial fibrillation in patients with paroxysmal supraventricular tachycardia. J Am Coll Cardiol. 1995 Apr;25(5):984-8. doi: 10.1016/0735-1097(94)00512-o.
Reference Type
BACKGROUND
Hamer ME, Blumenthal JA, McCarthy EA, Phillips BG, Pritchett EL. Quality-of-life assessment in patients with paroxysmal atrial fibrillation or paroxysmal supraventricular tachycardia. Am J Cardiol. 1994 Oct 15;74(8):826-9. doi: 10.1016/0002-9149(94)90448-0. No abstract available.
Reference Type
BACKGROUND
Linzer M, Gold DT, Pontinen M, Divine GW, Felder A, Brooks WB. Recurrent syncope as a chronic disease: preliminary validation of a disease-specific measure of functional impairment. J Gen Intern Med. 1994 Apr;9(4):181-6. doi: 10.1007/BF02600121.
Reference Type
BACKGROUND
Pritchett EL. Management of atrial fibrillation. N Engl J Med. 1992 May 7;326(19):1264-71. doi: 10.1056/NEJM199205073261906. No abstract available.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1118
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Characterization of Cardiac Electrophysiological Effects of Autonomic Neuromodulation
NCT05377216
RECRUITING
EARLY_PHASE1
Atrial Function and Supraventricular Arrhythmia of the Veteran Athlete.
NCT03665324
COMPLETED
Ventricular Tachycardia Mechanisms
NCT05478213
RECRUITING
NA
Proarrhythmic Medicines and Primary Cardiac Arrest
NCT00005253
COMPLETED
A Prospective Incident Study of Arrhythmias in Hypertrophic Cardiomyopathy
NCT04112290
ACTIVE_NOT_RECRUITING
Arrhythmic Manifestations and Management in Hospitalized COVID-19 Patients
NCT04465552
COMPLETED
Effects Rapid Atrial Pacing Has on the Electrocardiogram (ECG) in Patients With Dual Chamber Pacemakers
NCT00883610
COMPLETED
Cardiac Sympathetic Denervation for Prevention of Ventricular Tachyarrhythmias
NCT01013714
RECRUITING
PHASE3
Hypertrophic Cardiomyopathy Pilot Study
NCT02806479
COMPLETED
Identification of Risk Factors for Arrhythmia in Children and Adolescents With Hypertrophic Cardiomyopathy
NCT00753233
COMPLETED
Long Term Monitoring for Risk of Sudden Death
NCT04124237
COMPLETED
The PSVT Place Registry.Paroxysmal Supraventricular Tachycardia (PSVT) Registry.
NCT03353610
TERMINATED
Blood Pressure During Rate Control in Patients With Tachycardic Atrial Fibrillation at the Emergency Department
NCT04005482
UNKNOWN
Prognostic Significance of T Wave Alternans
NCT00006501
COMPLETED
Ventricular Tachycardia Cohort
NCT07149701
NOT_YET_RECRUITING
The Use of Dual Chamber ICD With Special Programmed Features to Lower the Risk of Inappropriate Shock
NCT00787800
COMPLETED
PHASE4
Systematic Assessment of Treatment Effectiveness for Long-Term Management of Stable Atrial Tachycardia in Inpatient and Outpatient Environments
NCT07239804
ACTIVE_NOT_RECRUITING
Study of Arrhythmia and ECG Abnormalities in Patients With COVID-19
NCT04937621
COMPLETED
Early Ablation Therapy for the Treatment of Ischemic Ventricular Tachycardia in Patients With Implantable Cardioverter Defibrillators
NCT01557842
TERMINATED
PHASE4
Ablation at Virtual-hEart pRedicted Targets for VT
NCT03536052
ACTIVE_NOT_RECRUITING
NA
Cardiac Arrhythmias at Extreme Altitude
NCT05676398
UNKNOWN
Non-invasive Differentiation of Supraventricular Tachyarrhythmia
NCT06061120
RECRUITING